Can-Fite's Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum
October 02 2013 - 7:00AM
Marketwired
Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a
biotechnology company developing a pipeline of small molecule drugs
that address inflammatory and cancer diseases, announced today that
Dr. Sari Fishman, the Director of Clinical Affairs of OphthaliX
Inc. (OTCQB: OPLI), its subsidiary, will deliver a company
presentation at the Ophthalmology Futures European Forumâ„¢ in
Amsterdam, The Netherlands. The conference brings together a
diverse panel of key members of the ophthalmology community,
including those from industry, academia and financial investment
practices, to discuss the future of ophthalmological specialties.
Dr. Sari Fishman's presentation will start at 5:00 pm on October
3rd, 2013, and will include information on OphthaliX's glaucoma
development program, which is currently in Phase II clinical trials
in the United States, Europe and Israel.
In addition to glaucoma, Can-Fite, on behalf of OphthaliX, in
which it holds approximately 82% of the issued and outstanding
common stock, is currently conducting Phase III clinical trials in
the United States, Europe and Israel for the treatment of dry eye
syndrome and is preparing for Phase II trials in Europe and Israel
for the treatment of uveitis. OphthaliX has exclusively licensed
the worldwide rights for Can-Fite's CF101 drug candidate for use in
ophthalmic indications.
"We are looking forward to OphthaliX presenting at the
Ophthalmology Futures European Forum," stated Can-Fite's Chief
Executive Officer, Dr. Pnina Fishman. "With the results of our
Phase III clinical trials for the treatment of dry eye syndrome
scheduled to be announced in the fourth quarter of this year, this
will be a great opportunity to present our current work in glaucoma
and to highlight CF101's potential for efficacy in the treatment of
several ophthalmic conditions. Many key members of the
ophthalmology community will be in attendance and presenting,
making the Forum a good place to interact with other innovators in
the industry."
About CF101
CF101, an A3 adenosine receptor agonist, is a novel, first in
class, small molecule, orally bioavailable drug which demonstrated
efficacy and an excellent safety profile in clinical studies.
Through a service arrangement with its parent, Can-Fite, OphthaliX
currently develops CF101 for the treatment of ophthalmic
indications, including dry eye syndrome (Phase III), glaucoma
(Phase II) and uveitis (initiating Phase II). CF101 is also
developed by Can-Fite for the treatment of autoimmune inflammatory
diseases, including, but not limited to, rheumatoid arthritis
(Phase IIb) and psoriasis (Phase II/III).
About OphthaliX Inc.
OphthaliX Inc. is a clinical-stage biopharmaceutical company
focused on developing therapeutic products for the treatment of
ophthalmic disorders. OphthaliX's product candidate CF101, is being
developed to treat three ophthalmic indications: dry eye syndrome;
glaucoma; and uveitis.
About Can-Fite Biopharma Ltd.
Can-Fite Biopharma Ltd is an Israeli public company, the
ordinary shares of which are traded on the Tel Aviv Stock Exchange
(the "TASE") (TASE: CFBI). Level II American Depository Receipts of
the company are traded on the U.S. Over-the-Counter Markets (the
"OTC Markets") (OTCQB: CANFY). Can-Fite, which commenced business
activity in 2000, was founded by Pnina Fishman, Ph.D., researcher
in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney
and senior partner at Reinhold Cohn Patent Attorneys in Israel. Dr.
Fishman serves as the Chief Executive Officer of Can-Fite. Dr.
Fishman founded Can-Fite on the basis of her scientific findings,
and Can-Fite is focused on the development of small molecule orally
bioavailable drugs, in particular, ligands that bind to the A3
adenosine receptor. Such drugs mediate anti-inflammatory and
anti-cancer effects and are suggested as a biological predictive
marker. Can-Fite's lead drug candidate, CF101, is in clinical
development for the treatment of autoimmune inflammatory diseases.
Can-Fite's CF102 drug candidate is being developed for the
treatment of liver diseases and its CF602 drug is being developed
for the treatment of inflammation and sexual dysfunction. To date,
more than 700 patients have participated in clinical trials
conducted by Can-Fite. Can-Fite previously licensed its activity in
the ophthalmic field to OphthaliX Inc., in which it holds a
controlling interest and which is currently listed on the OTC
Markets (OTCQB: OPLI).
Safe Harbor Statement
This press-release contains forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. In
addition, from time to time, Can-Fite or its representatives have
made or may make forward-looking statements, orally or in writing.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact
that these statements do not relate strictly to historical or
current matters. These forward-looking statements may be included
in, but are not limited to, various filings made by Can-Fite with
the U.S. Securities and Exchange Commission (the "SEC"), press
releases or oral statements made by or with the approval of one of
Can-Fite's authorized executive officers. Forward-looking
statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and
uncertainties that could cause Can-Fite's actual results to differ
materially from any future results expressed or implied by the
forward-looking statements. Many factors could cause Can-Fite's
actual activities or results to differ materially from the
activities and results anticipated in such forward-looking
statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with
the TASE.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact IRTH Communications Robert Haag Email Contact
1-866-976-IRTH (4784)